Views & Analysis Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results... Last month, pharmaphorum spoke with Dr Charles C.
News Syndax shares fall as lung fibrosis drug fails trial Syndax shares lost 17% of their value pre-market after the company said it abandoned development of axatilimab for idiopathic pulmonary fibrosis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
